TearClear Announces Positive Topline Results From Clear Phase 3 Study for the Treatment of Glaucoma
TearClear, an ophthalmic pharmaceutical company that transforms trusted drugs into branded best-in-class therapies, announced that the company’s will file a NDA with the FDA on their lead product. This product will offer patients the first and only means of delivering preservative-free doses of latanoprost from conventional multi-dose bottles.
World Glaucoma Week: A Retina Specialist’s Guide to Recent Innovations in Glaucoma
Ophthalmologists and researchers have made great strides in the management of glaucoma. From implants and robotics to proper administration of eye drops, glaucoma is treated more effectively than ever. This article highlights some of the latest discoveries in glaucoma, including work by UF startup and Sid Martin Biotech company TearClear.
TearClear Announces Initiation of TC-002 Latanoprost Ophthalmic Solution Phase 3 Trial
TearClear has announced the TC-002 phase 3 trial has been successfully initiated. TearClear’s phase 3 trial (CLEAR Study) is a prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, 3-month study assessing the safety and ocular hypotensive efficacy of TC-002 ophthalmic solution (TearClear Preservative-Free Latanoprost Ophthalmic Solution 0.005%) compared to marketed Latanoprost ophthalmic solution 0.005%.
New and Upcoming Developments in Glaucoma Treatment
Glaucoma specialist, Dr. Amy Mehta, discusses new and upcoming developments in glaucoma treatment, including an advance by UF startup and UF Innovate | Accelerate at Sid Martin Biotech company TearClear.
TearClear Files Investigational New Drug (IND) Application To Begin Its Clinical Trial for TC-002 Latanoprost Ophthalmic Solution, 0.005%
UF startup and UF Innovate | Sid Martin Biotech company TearClear, a late clinical-stage ophthalmic pharmaceutical company, has filed an Investigational New Drug (IND) application to conduct a registrational study for its lead glaucoma candidate, TC-002 latanoprost ophthalmic solution, 0.005%.
Stuart Raetzman Appointed as Interim CEO at TearClear
UF startup and UF Innovate | Sid Martin Biotech resident client TearClear has appointed Stuart Raetzman as interim CEO and is preparing for a pivotal study on proprietary latanoprost for glaucoma treatment, according to a press release.
TearClear Moving Toward Clinical Trials and Strengthening Leadership Team
UF startup and UF Innovate | Sid Martin Biotech resident client TearClear, an emerging ophthalmic pharmaceutical company, continues to make progress on the development of its first-in-class platform of preservative-free topical medications.
TearClear Announces Successful Completion of Pre-IND Meeting With the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma
UF startup and UF Innovate | Sid Martin Biotech resident client TearClear, an emerging ophthalmic pharmaceutical company, announced successful completion of pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development plan for the preservative free multi-dose delivery of a proprietary Latanoprost formulation, including the clinical study design for the registration study.
TearClear Appoints Robert Bailey to Board of Directors
UF startup and UF Innovate | Sid Martin Biotech resident client TearClear, a global ophthalmic pharmaceutical company, announces the appointment of industry veteran... Read More
TearClear Raises $22 Million to Advance Multiple Clinical Programs in Development
UF startup and UF Innovate | Sid Martin Biotech resident client TearClear, a global ophthalmic pharmaceutical company, has raised $22M in a... Read More
